This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Clinical Trial

. 1971 Dec;4(1):18-21.

doi: 10.1007/BF00568893.

Levodopa and orphenadrine hydrochloride in Parkinsonism

R K Whyte, K R Hunter, D R Laurence, G M Stern, P Armitage

PMID: 4948768
DOI: 10.1007/BF00568893

Clinical Trial

Levodopa and orphenadrine hydrochloride in Parkinsonism

R K Whyte et al. Eur J Clin Pharmacol. 1971 Dec.

. 1971 Dec;4(1):18-21.

doi: 10.1007/BF00568893.

Authors

R K Whyte, K R Hunter, D R Laurence, G M Stern, P Armitage

PMID: 4948768
DOI: 10.1007/BF00568893

No abstract available

PubMed Disclaimer

Similar articles

Injected apomorphine and orally administered levodopa in Parkinsonism.
Düby SE, Cotzias GC, Papavasiliou PS, Lawrence WH. Düby SE, et al. Arch Neurol. 1972 Dec;27(6):474-80. doi: 10.1001/archneur.1972.00490180010004. Arch Neurol. 1972. PMID: 4563448 Clinical Trial. No abstract available.
Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism.
Mindham RH, Gaind R, Anstee BH, Rimmer L. Mindham RH, et al. Psychol Med. 1972 Nov;2(4):406-13. doi: 10.1017/s0033291700045220. Psychol Med. 1972. PMID: 4571143 Clinical Trial. No abstract available.
Levodopa for parkinsonism in elderly and demented patients.
Broe GA, Caird FI. Broe GA, et al. Med J Aust. 1973 Mar 31;1(13):630-5. doi: 10.5694/j.1326-5377.1973.tb110594.x. Med J Aust. 1973. PMID: 4702182 No abstract available.
Pyridoxine, DOPA, and Parkinsonism.
Yahr MD, Duvoisin RC, Côté L, Cohen G. Yahr MD, et al. Adv Biochem Psychopharmacol. 1972;4:185-94. Adv Biochem Psychopharmacol. 1972. PMID: 4555927 Review. No abstract available.
[Long term treatment of a parkinsonism with l-dopa].
Presthus J. Presthus J. Tidsskr Nor Laegeforen. 1973 Oct 10;93(28):2111-3. Tidsskr Nor Laegeforen. 1973. PMID: 4590069 Review. Norwegian. No abstract available.

See all similar articles

Cited by

Striatal cholinergic interneuron regulation and circuit effects.
Lim SA, Kang UJ, McGehee DS. Lim SA, et al. Front Synaptic Neurosci. 2014 Oct 21;6:22. doi: 10.3389/fnsyn.2014.00022. eCollection 2014. Front Synaptic Neurosci. 2014. PMID: 25374536 Free PMC article. Review.
Anticholinergics for symptomatic management of Parkinson's disease.
Katzenschlager R, Sampaio C, Costa J, Lees A. Katzenschlager R, et al. Cochrane Database Syst Rev. 2003;2002(2):CD003735. doi: 10.1002/14651858.CD003735. Cochrane Database Syst Rev. 2003. PMID: 12804486 Free PMC article.
Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.
Young BK, Camicioli R, Ganzini L. Young BK, et al. Drugs Aging. 1997 May;10(5):367-83. doi: 10.2165/00002512-199710050-00005. Drugs Aging. 1997. PMID: 9143857 Review.
Targeting the cholinergic system in Parkinson's disease.
Liu C. Liu C. Acta Pharmacol Sin. 2020 Apr;41(4):453-463. doi: 10.1038/s41401-020-0380-z. Epub 2020 Mar 4. Acta Pharmacol Sin. 2020. PMID: 32132659 Free PMC article. Review.

References

1. Lancet. 1970 Sep 12;2(7672):566 - PubMed
1. Lancet. 1969 Nov 8;2(7628):973-6 - PubMed
1. Lancet. 1970 May 30;1(7657):1127-9 - PubMed
1. N Y State J Med. 1970 Sep 15;70(18):2309-18 - PubMed
1. Br Med J. 1970 Oct 10;4(5727):93-4 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer